Lipid-Modified Nucleic Acids for Low-Toxicity Cellular Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Delivering therapeutic nucleic acids into cells remains a challenging area of research, necessitating improved nucleic acid compounds and strategies for effective introduction.
Innovation Solution
Lipid-modified nucleic acid compounds, such as those with specific structural modifications, are introduced into cells under free uptake conditions, enhancing cellular uptake and expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional nucleic acid delivery methods are used, then delivery efficiency is low, but cellular toxicity is also reduced
Solution Approach 1:
The patent modifies the chemical parameters of nucleic acid compounds by incorporating lipid conjugates with specific chain lengths (C10-C22), degrees of unsaturation, and head group compositions. These parameter changes enhance cellular uptake efficiency while the systematic optimization of lipid structure prevents excessive toxicity, resolving the contradiction between delivery efficiency and cellular safety
Solution Approach 2:
The invention creates composite nucleic acid-lipid structures where nucleic acid molecules are conjugated to lipid molecules through linkers. This composite structure combines the therapeutic function of nucleic acids with the membrane-interacting properties of lipids, enabling efficient cellular delivery without the high toxicity associated with conventional delivery methods
2Productivity
If lipid-modified nucleic acid compounds are used, then cellular uptake is enhanced, but compound complexity increases
Solution Approach 1:
The lipid-modified nucleic acid compound is segmented into distinct functional modules: a nucleic acid moiety (A), a linker (L1-L2-L3-L4), and a lipid moiety (L5-L6 with R1-R6 groups). This segmentation allows each component to be independently optimized for its specific function while maintaining overall compound manageability and synthesis feasibility
Solution Approach 2:
The patent develops a universal platform where the same lipid conjugation strategy can be applied to various nucleic acid types (siRNA, antisense oligonucleotides, mRNA). The modular design with interchangeable lipid groups (saturated, unsaturated, PEGylated) provides multi-functionality, enabling the same core structure to achieve enhanced cellular uptake across different therapeutic nucleic acid applications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lipid-modified nucleic acid compounds effectively introduce and express therapeutic nucleic acids within cells, demonstrating significant reduction in target mRNA levels, as shown in various cell types and animal models.
Implementation Method 1
Lipid-modified nucleic acid compounds, such as those with specific structural modifications, are introduced into cells under free uptake conditions, enhancing cellular uptake and expression
Data Source
AI summary
Disclosed herein, inter alia, are lipid-modified nucleic acid compounds, their preparation, and their use.